DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...

The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...

Accelerated sequencing technologies, AI-enabled analytics, newborn screening expansion, and government-backed genomic initiatives fuel rapid growth across North America, Europe, and ...

Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted ...

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Among pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL), the removal of total body irradiation (TBI) from conditioning did not compromise efficacy, and was comparable ...

Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.

A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...